Search

Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!

FDA approves treatment option for T2D in children 10 and older

FDA has approved Jardiance® (empagliflozin) tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. See Safety, PI & Med Guide.

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US

An FDA study found that PRADAXA was associated with reduced risks of ischemic stroke, intracranial hemorrhage & death. View ISI, PI & Med Guide.

Search

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis

Boehringer Ingelheim Launches External Innovation Hub in China

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Boehringer Ingelheim: Discover the app set to transform animal care in rural India

FDA approves treatment option for T2D in children 10 and older

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis

Boehringer Ingelheim Launches External Innovation Hub in China

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Boehringer Ingelheim: Discover the app set to transform animal care in rural India

FDA approves treatment option for T2D in children 10 and older

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US